Completed
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate cancer and are Associated with Early Age at Death
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Prostate Cancer Genetic Risk Assessment - Webinar - Ambry Genetics
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Disclosures
- 3 Three Inherited Risk Measures
- 4 Genetic Risk Score
- 5 Does GRS Work?
- 6 Broad-sense Validity
- 7 Narrow-sense Validity
- 8 Current Clinical Practice
- 9 Hypothesis for the Need
- 10 Direct Evidence from UKB
- 11 GRS of PCa in UKB
- 12 RPMs of PCa in UKB
- 13 Association with PCa Risk/Mortality
- 14 Simple and Clean Analysis
- 15 PCa Diagnosis-free Survival
- 16 Benefits of Genetic Assessment in
- 17 Predicting Risk: PCa Screening
- 18 Rare Pathogenic Mutations (RPMs)
- 19 Consistent Evidence for HOXB13
- 20 Evidence for Prostate Cancer Susceptibility Genes
- 21 Cumulative Effects of 100 SNPs
- 22 GRS Modifies BRCA2 Effect in PCa
- 23 Predicting Prognosis: Early Stage
- 24 Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate cancer and are Associated with Early Age at Death
- 25 Predicting Therapeutic Responses: Late Stage
- 26 BRCA2 mutations and Response to Carboplatin-based Therapy
- 27 High Levels of Microsatellite instability (MSI-H) and DNA Mismatch Repair Gene (MMR) Mutations: Actionable with Anti-PD-L1 agents
- 28 Conclusions
- 29 Case Example
- 30 Management?
- 31 Surgical Specimen
